BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 9256133)

  • 1. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
    Pauletti G; Godolphin W; Press MF; Slamon DJ
    Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.
    Xing WR; Gilchrist KW; Harris CP; Samson W; Meisner LF
    Breast Cancer Res Treat; 1996; 39(2):203-12. PubMed ID: 8872329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
    Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
    Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
    Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
    Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer.
    Onody P; Bertrand F; Muzeau F; Bièche I; Lidereau R
    Arch Pathol Lab Med; 2001 Jun; 125(6):746-50. PubMed ID: 11371225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
    Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
    Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
    Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
    Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
    Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].
    Scheer M; Prange W; Petmecky K; Schirmacher P; Zöller JE; Kübler AC
    Mund Kiefer Gesichtschir; 2003 May; 7(3):138-45. PubMed ID: 12764679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
    Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL; Borelli KA; Hsu PH
    Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.
    Chang E; Lee A; Lee E; Lee H; Shin O; Oh S; Kang C
    J Korean Med Sci; 2004 Jun; 19(3):390-6. PubMed ID: 15201505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.